Navigation Links
Potential gene therapy for Sickle cell disease
Date:7/2/2013

Sickle cell disease (SCD) is an autosomal recessive disorder caused by mutations in hemoglobin (HBB) that deform red blood cells. A small number of patients have been successfully treated with allogeneic hematopoietic stem cell (HSC) transplantation; however, there are several drawbacks and complications associated with this procedure, including graft vs. host disease and long-term immune suppression. Many of complications could potentially be avoided by the use of autologous HSC transplant, which uses patient cells that have been treated genetically modified to replace defective hemoglobin. In this issue of the Journal of Clinical Investigation, Zulema Romero and colleagues investigated the utility of a genetic vector encoding a human hemoglobin gene engineered to impede sickle hemoglobin and prevent the sickling of red blood cells. The vector was used to efficiently transduce bone marrow cells from SCD patients and the transduced cells were successfully transplanted into immunocompromised mice, suggesting that this method could potentially be used to treat SCD.


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Dual-acting class of antimalarial compounds discovered with potential to prevent and treat malaria
2. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
3. Carnegie Mellon study reveals potential of manganese in neutralizing deadly Shiga toxin
4. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
5. Carbon capture and storage -- new research from UKERC shows tough road ahead to realize potential
6. Researchers Find Potential Link Between Drinking Alcohol And Breast Cancer
7. Golden potential for gold thin films
8. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
9. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
10. Welcome to BIO-Poland Explore Our Potential
11. AstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... LONDON , August 3, 2015 ... Portland Hospital waved the shortfall of ... fanatic could stand normally for the first time. ...      (Photo: http://photos.prnewswire.com/prnh/20150803/254229 ) The ... Jude,s legs allowing him to carry out his wish ...
(Date:8/3/2015)... , Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: ... to treat life-threatening diseases, today announced that it will ... and webcast on Thursday, August 13, 2015 at 4:30 ... will follow the release of fiscal 2016 first quarter ... available approximately two hours after the call at the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces the ... line of analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, ... resistant and maintenance-free solution for a broad range of vacuum filtration applications. , ...
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
Breaking Biology Technology:Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Sterlitech Launches New Line of Vacuum Pumps 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... a privately,held biotechnology company, announced that it has ... Series D preferred stock offering with its investor,syndicate ... Ventures,L.P., Boston Medical Investors and Silicon Valley Bank ... Chairman of the Board. The Company,expects a second ...
... Application in the ... European Union, ... Food and Drug Administration (FDA) has approved the design of,a single, ... with chemotherapy as first-line,treatment in patients with non-small cell lung cancer ...
... 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL) today ... for its asthma management product, Aridol., "This ... Pharmaxis Chief,Executive Officer Dr Alan Robertson. "Korea is ... Aridol in Asia. There are an estimated 2.5 ...
Cached Biology Technology:Peptimmune Announces First Close of Series D Private Financing 2Peptimmune Announces First Close of Series D Private Financing 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 2Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 3Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 4Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer 5Pharmaxis' Aridol Gains First Asian Approval 2
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... (Sept. 4, 2008) A variety of organismsfrom ... where the timing and duration of fundamental biological processes ... survive, even under fluctuating environmental conditions. In recent ... molecular basis of these rhythms and how they translate ...
... Breast Cancer Symposium features the latest cutting-edge findings in ... meeting focuses on new and promising therapeutic approaches, as ... breast cancer. To help you take the best ... we encourage you to visit www.sabcs.org to ...
... September 4, 2008) The tumor suppressor gene ... in cases of soft tissue sarcoma (STS), according ... at the Sbarro Institute for Cancer Research and ... Technology at Temple University in Philadelphia, PA, the ...
Cached Biology News:Interdisciplinary volume on biological rhythms serves as both primer and in-depth resource 2International team reveals first prognosticator of survival in aggressive cancer 2
... 1;heading 2;Many mammalian ... experimental situations create ... transfection and other ... ViraPower Lentiviral Expression ...
LTBP-2 (7B10)...
... Product Rabbit polyclonal to Kv4.2 ... to KLH, corresponding to amino acids 23-43 ... Cross-reacts with Rat.Expected to cross-react with ... identity with immunogen), Rabbit (100% identity with ...
Mouse Anti-Gemin2...
Biology Products: